AMR Ac­tion Fund looks to tack­le an­timi­cro­bial re­sis­tance with first two in­vest­ments — but does the mon­ey ar­rive too late?

The AMR Ac­tion Fund — backed by a hand­ful of heavy­weight phar­ma play­ers in­clud­ing Pfiz­er, Eli Lil­ly, Mer­ck, John­son & John­son, Boehringer In­gel­heim and Glax­o­SmithK­line — has made its first two in­vest­ments in the hopes of ad­dress­ing the loom­ing threat of an­timi­cro­bial re­sis­tance.

But ac­cord­ing to CEO Hen­ry Skin­ner, there’s plen­ty more to go around this year.

AMR has promised to in­vest over $100 mil­lion this year in com­pa­nies de­vel­op­ing an­timi­cro­bials that can over­come re­sis­tance, start­ing with Adap­tive Phage Ther­a­peu­tics (APT) and Ve­na­torx Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER